Cellectar Biosciences, Inc.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As described in Item 5.07 below, on July 7, 2026, at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Cellectar Biosciences, Inc. (the “Company”), the Company’s stockholders approved an amendment to the Company’s 2021 Stock Incentive Plan (the “Plan”) to increase the number of shares reserved for issuance under the Plan by 2,000,000 shares. A copy of the Plan, as amended, is filed as Exhibit 10.1 to this Current Report and is incorporated by reference in this Item 5.02.

Item 5.07. Submission of Matters to a Vote of Security Holders The Company held the Annual Meeting at 10:00 a.m., local time, on July 7, 2026. The proposals presented for stockholder approval at the Annual Meeting are described below: Proposal No. 1 - Election of Directors Class III directors, Andrew Gu and Douglas J. Swirsky, were nominated and elected to serve three-year terms. The vote was as follows: Nominee For Withhold Broker Non-Votes ───────────────────────────────────────────────────────────────────────── Adnrew Gu 2,134,395 25,493 1,382,976 Douglas J. Swirsky 2,126,590 33,298 1,382,976 Proposal No. 2 - Approval of an Increase in the Number of Shares Available for Issuance Under the 2021 Stock Incentive Plan The Company requested approval of an increase in the number of shares of common stock available for issuance under the Plan by 2,000,000 shares. The stockholders approved the proposal. The vote was as follows: For Against Abstain Broker Non-Votes ───────────────────────────────────────────────────────────── 1,706,640 439,422 13,825 1,382,977 Proposal No. 3 - Ratification of Appointment of Independent Registered Public Accounting Firm The Company requested ratification of the appointment by the Audit Committee of the Board of Directors of Deloitte & Touche LLP to be the Company’s independent registered public accounting firm for fiscal year 2026. The stockholders ratified the appointment. The vote was as follows: For Against Abstain ─────────────────────────────────────── 3,518,084 13,956 10,824 Proposal No. 4 - Approval of Executive Officer Compensation The Company requested approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. The stockholders approved the compensation of the named executive officers. The vote was as follows: For Against Abstain Broker Non-Votes ───────────────────────────────────────────────────────────── 1,438,422 712,362 9,102 1,382,978 Proposal No. 5 - Approval of Exercise of Warrants The Company requested approval the exercise of warrants issued by the Company to purchase up to an aggregate of 39,618,078 shares of common stock under applicable rules and regulations of the Nasdaq Stock Market LLC (the “Warrant Exercise Proposal”). The stockholders approved the proposal. The vote was as follows: For Against Abstain Broker Non-Votes ───────────────────────────────────────────────────────────── 1,881,936 55,004 222,946 1,382,977 Proposal No. 6 - Adjournment of Annual Meeting Because the Warrant Exercise Proposal was approved, the sixth proposal on the agenda regarding adjournment of the Annual Meeting was rendered moot and was not presented.